Compare Abeona Therapeutics Inc (ABEO) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Koninklijke Philips NV — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Koninklijke Philips NV trades at $27.55 (market cap $27.30B). The key difference: Koninklijke Philips NV is far larger — about 73.1× Abeona Therapeutics Inc's market cap, and Koninklijke Philips NV pays a 3.59% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | PHG | |
|---|---|---|
Market Cap | $373.32M | $27.30B |
Sector | Health | Health |
52-Week High | $7.23 | $32.91 |
52-Week Low | $4.17 | $24.03 |
Enterprise Value | $228.22M | $33.57B |
Dividend Yield | — | 3.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
PHG trades at $28.23, up 1.77% with a bullish technical outlook supported by moving averages. The company shows improved profitability with net income turning positive at $895 million in 2025 after previous losses. Recent earnings beat expectations in two of the last three quarters, while analyst sentiment leans neutral with 40.9% buy ratings. Strong cash flow generation and strategic partnerships in healthcare technology position the company for continued recovery.
The stock presents a recovery story with improving fundamentals but faces execution risks in a competitive healthcare technology market. Valuation appears reasonable with P/E of 24.73 and P/S of 1.35, though debt levels remain elevated. Near-term catalysts include Q2 2026 earnings and continued AI integration in healthcare solutions, while macroeconomic pressures and competitive threats represent ongoing challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
